It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ) . Shares have added about 24.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Jazz due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Q3 Earnings & Sales Beat EstimatesJazz Pharma ...

Core Insights - Jazz Pharmaceuticals announced the presentation of eight abstracts, including four late-breaking ones, at the American Epilepsy Society (AES) 2025 Annual Meeting, focusing on the efficacy of Epidiolex (cannabidiol) in treating rare forms of epilepsy [1][2][3] Group 1: EpiCom Trial Results - The EpiCom trial, a Phase 3b/4 study, showed promising reductions in behavioral problems associated with tuberous sclerosis complex (TSC) after 26 weeks of Epidiolex treatment, as indicated by improvements in TAND-SQ and ABC subscale scores [2][3] - The trial utilized novel endpoints that focused on individualized outcomes, addressing the specific problematic behaviors identified by caregivers and clinicians [3] Group 2: Additional Highlights from AES 2025 - A late-breaking poster presented results from a Phase 1 study that found no pharmacokinetic interactions between Epidiolex and cenobamate when administered together [4] - Preclinical data demonstrated a novel synergistic pharmacodynamic interaction between Epidiolex and cenobamate in a mouse model of seizures [4] - Real-world effectiveness data indicated that initiating Epidiolex in CBD-naïve patients with Dravet Syndrome, Lennox-Gastaut Syndrome, or TSC led to reduced polypharmacy and healthcare resource utilization after 12 months [4] - A post-hoc analysis from the Expanded Access Program showed that Epidiolex treatment was associated with reductions in seizure frequency in patients with developmental and epileptic encephalopathies [4] Group 3: Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing innovative medicines for serious diseases, including epilepsy, with a commitment to addressing the needs of patients with limited therapeutic options [21]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of complex financial instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information does not constitute a recommendation or advice for investment actions [1]. - Users are encouraged to understand the risks involved with financial instruments before making investment decisions [1]. Group 2 - The website highlights that cryptocurrencies and CFDs are complex instruments with a high risk of losing money [1]. - It advises users to carefully consider their understanding of these instruments and their financial capacity to absorb potential losses [1]. - The content may not be provided in real-time and is not guaranteed to be accurate, indicating a need for users to verify information independently [1].

Accessibility StatementSkip Navigation Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data For U.S. media and investors only DUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera (zanidatamab-hrii) have been accepted for presentation at the American Society of Cli ...

PresentationCiti Annual Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're pleased to have Jazz Pharmaceuticals with us. We have Philip Johnson, EVP and CFO. So welcome Phil. And then, we have Jack Spinks from Jazz as well. So thank you, guys for joining us.Philip JohnsonExecutive VP & CFO Happy to. Thank you very much for the invite. Pleasure to be here at the conference. In addition to having Jack with me from our IR team, I also want to give a shout out t ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) FY 2025 Conference December 02, 2025 09:45 AM ET Company ParticipantsJack Spinks - Executive Director of Investor RelationsPhilip Johnson - EVP and CFOConference Call ParticipantsGeff Meach - Senior Biopharma AnalystGeff MeachJust my name is Geff Meach. I'm the Senior Biopharma Analyst here. We're pleased to have Jazz Pharmaceuticals with us. We have Phil Johnson, EVP and CFO, so welcome, Phil. We have Jack Spinks from Jazz as well. Thank you, guys, for joining us. Phil, ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) FY 2025 Conference December 02, 2025 09:45 AM ET Company ParticipantsJack Spinks - Executive Director of Investor RelationsPhilip Johnson - EVP and CFOConference Call ParticipantsGeff Meach - Senior Biopharma AnalystGeff MeachJust my name is Geff Meach. I'm the Senior Biopharma Analyst here. We're pleased to have Jazz Pharmaceuticals with us. We have Phil Johnson, EVP and CFO, so welcome, Phil. We have Jack Spinks from Jazz as well. Thank you, guys, for joining us. Phil, ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) FY 2025 Conference December 02, 2025 09:45 AM ET Speaker0Just my name is Jeff Beach. I'm the Senior Biopharma Analyst here. We're pleased to have Jazz Pharmaceuticals with us. We have Phil Johnson, EVP and CFO, so welcome, Phil. We have Jack Spinks from Jazz as well. Thank you, guys, for joining us. Phil, you want to kick it off with some kind of opening comments, and we can get right into some questions.Speaker2Happy to. Thank you very much for the invite. It's a pleasu ...

Core Insights - JAZZ Pharmaceuticals is an unconventional player in the cannabis sector, having entered the market through the acquisition of GW Pharmaceuticals in 2021, which added the FDA-approved CBD drug Epidiolex to its portfolio [1][2] - The company is well-positioned for long-term gains as the medical cannabis market evolves and regulatory clarity improves [2] Epidiolex's Contribution - Epidiolex has become a significant revenue contributor, accounting for a quarter of JAZZ's total revenues [3] - In the first nine months of 2025, Epidiolex generated over $772 million in product sales, reflecting an 11% year-over-year increase [4] - The global medical cannabis market is projected to exceed $130 billion by 2032, providing JAZZ with a unique opportunity due to its established FDA-approved product [5] Diverse Product Lineup - JAZZ has a diverse product lineup beyond cannabis, including drugs for neuroscience and oncology [6] - Xywav, a low-sodium formulation for narcolepsy, is a key product that offers advantages over its predecessor, Xyrem [7] - The oncology segment includes six drugs that now contribute over 26% to JAZZ's topline, driven by new launches and increased market share [8] Pipeline Developments - JAZZ is focused on expanding the labels of its oncology drugs, with promising results for Ziihera in treating HER2+ gastroesophageal adenocarcinoma [9] - Despite setbacks in its pipeline, including the discontinuation of suvecaltamide and underwhelming results for JPZ150, the company continues to explore options for its drug development [12][13] Stock Performance and Outlook - JAZZ's stock has surged 46% year-to-date, outperforming the industry average of 20% [14] - EPS estimates for 2025 and 2026 have trended upward, indicating a stronger outlook compared to other cannabis-focused companies [15] - The company offers a diversified revenue base, making it suitable for investors seeking balanced biotech exposure rather than a direct cannabis investment [16][17]

Core Insights - The article compiles significant research calls from Wall Street, highlighting upgrades and downgrades of various companies that investors should be aware of [1] Upgrades - Wells Fargo upgraded Merck (MRK) to Overweight from Equal Weight with a price target of $125, increased from $90, citing business development and pipeline progress as key factors for revenue growth in the early 2030s [2] - Wolfe Research upgraded Morgan Stanley (MS) to Outperform from Peer Perform with a price target of $198, anticipating accelerated revenue growth from investment banking share gains and organic growth in wealth management [3] - HSBC upgraded Flutter Entertainment (FLUT) to Buy from Hold with a price target of $228, reduced from $265, viewing the recent share selloff as a buying opportunity [3] - BofA upgraded Booking Holdings (BKNG) to Buy from Neutral with an unchanged price target of $6,000, believing that concerns regarding disintermediation risks from Google and OpenAI are overstated [4] - Wedbush upgraded Carvana (CVNA) to Outperform from Neutral with a price target of $400, increased from $380, suggesting that the recent share pullback is overdone [5] Downgrades - UBS downgraded JFrog (FROG) to Neutral from Buy with a price target of $65, up from $48, indicating that while AI-related benefits are significant, the larger revenue impact is likely 12-18 months away [6] - Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90, due to the pending acquisition by Abbott, which is seen as a win for Exact Sciences [6] - Evercore ISI downgraded QuantumScape (QS) to In Line from Outperform with a price target of $12, up from $8, citing valuation concerns as shares have risen 200% year-to-date [6] - UBS downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Buy with a price target of $188, up from $163, stating that the stock appears fairly valued after a strong Phase 3 GEA update and a 25% stock increase [6] - TD Cowen downgraded PureCycle Technologies (PCT) to Hold from Buy with a price target of $9, down from $16, due to delays in orders and growth plans, prompting a more cautious stance [6]